2015
Activation of Protein Kinase A in Mature Osteoblasts Promotes a Major Bone Anabolic Response
Tascau L, Gardner T, Anan H, Yongpravat C, Cardozo CP, Bauman WA, Lee FY, Oh DS, Tawfeek HA. Activation of Protein Kinase A in Mature Osteoblasts Promotes a Major Bone Anabolic Response. Endocrinology 2015, 157: 112-126. PMID: 26488807, DOI: 10.1210/en.2015-1614.Peer-Reviewed Original ResearchMeSH KeywordsAMP-Activated Protein KinasesAnimalsBone DensityCells, CulturedEnergy MetabolismEnzyme ActivationFemaleFemurLumbar VertebraeMaleMice, Inbred C57BLMice, TransgenicOsteoblastsOsteocytesOsteogenesisPoint MutationPromoter Regions, GeneticSex CharacteristicsUp-RegulationX-Ray MicrotomographyConceptsBone anabolic responseOb miceMature osteoblastsPKA activationHigher basal PKA activityControl miceAnabolic responseProtein kinase ASerum bone turnover markersBone volume/total volumeBone turnover markersBasal PKA activityFemur cortical thicknessTotal tissue areaActive PKAKinase AConstitutive activationPKA activityTurnover markersBone lossAnabolic drugsStructure model indexOsteoclast numberFemale miceBone mass
2014
Proteomic identification of 14‐3‐3ϵ as a linker protein between pERK1/2 inhibition and BIM upregulation in human osteosarcoma cells
Kim KO, Hsu AC, Lee HG, Patel N, Chandhanayingyong C, Hickernell T, Lee F. Proteomic identification of 14‐3‐3ϵ as a linker protein between pERK1/2 inhibition and BIM upregulation in human osteosarcoma cells. Journal Of Orthopaedic Research® 2014, 32: 848-854. PMID: 24536031, DOI: 10.1002/jor.22598.Peer-Reviewed Original ResearchConceptsPERK1/2 inhibitionHuman osteosarcoma cellsBim expressionSubset of patientsOsteosarcoma cellsConventional cytotoxic agentsConventional cytotoxic treatmentAnti-cancer effectsInhibition of pERK1/2Pro-apoptotic mechanismsMultifocal osteosarcomaMultimodality chemotherapyCytotoxic treatmentUpregulation of BimOsteosarcoma treatmentOsteosarcoma cell deathCytotoxic agentsExpression of BimPotential mediatorsTreatment of PD98059UpregulationTreatmentPD98059 treatmentInhibitionCell death
2011
Interleukin‐1β stimulates stromal‐derived factor‐1α expression in human subacromial bursa
Blaine TA, Cote MA, Proto A, Mulcahey M, Lee FY, Bigliani LU. Interleukin‐1β stimulates stromal‐derived factor‐1α expression in human subacromial bursa. Journal Of Orthopaedic Research® 2011, 29: 1695-1699. PMID: 21484857, DOI: 10.1002/jor.21416.Peer-Reviewed Original ResearchConceptsHuman subacromial bursaIL-1βIL-6SDF-1α expressionRotator cuff diseaseSubacromial bursaSubacromial bursitisSDF-1α productionSDF-1αCuff diseaseSDF-1α mRNA expressionBursal cellsInterleukin IL-1βSubacromial bursal tissueDose-dependent increaseFactor-1α expressionAnti-human antibodiesSupernatants of cellsRheumatoid controlsLocal cytokinesInflammatory cellsShoulder surgeryInterleukin-1βInflammatory responseIL-1Targeting Inflammatory Kinase as an Adjuvant Treatment for Osteosarcomas
Noh K, Kim KO, Patel NR, Staples JR, Minematsu H, Nair K, Lee FY. Targeting Inflammatory Kinase as an Adjuvant Treatment for Osteosarcomas. Journal Of Bone And Joint Surgery 2011, 93: 723-732. PMID: 21508279, PMCID: PMC6882535, DOI: 10.2106/jbjs.j.00302.Peer-Reviewed Original ResearchConceptsOsteosarcoma-bearing miceDoxorubicin treatmentVehicle-treated control miceVehicle-treated miceSubset of patientsConventional cytotoxic chemotherapyCell deathOsteosarcoma cellsAnti-cancer effectsAnti-apoptotic protein expressionSignal-regulated kinase 1/2Bcl-2-mediated resistanceInflammatory kinasesAdjuvant treatmentCytotoxic chemotherapyUntreated miceControl miceTreatment outcomesTherapeutic effectERK pathway inhibitorAnti-apoptotic proteinsNude miceAnimal morbidityAggressive osteosarcomaOsteosarcoma cell death